Tumor dosimetry using [124I]miodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model

Molecular Imaging and Biology

Volumn 14, Issue 6, 2012, Pages 735-742

  Seo, Youngho ^a,b   Gustafson, W Clay ^a   Dannoon, Shorouk F ^a   Nekritz, Erin A ^a   Lee, Chang Lae ^c   Murphy, Stephanie T ^a   Van Brocklin, Henry F ^a   Hernandez Pampaloni, Miguel ^a   Haas Kogan, Daphne A ^a   Weiss, William A ^a   Matthay, Katherine K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Yonsei University Wonju   (South Korea)

Author keywords

Animal model; Iodine 124; Iodine 131; M iodobenzylguanidine; Neuroblastoma; PET CT; Radiation dosimetry

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; IODINE 3 IODOBENZYLGUANIDINE I 214; NORADRENALIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG UPTAKE; EMBRYO; HUMAN; HUMAN CELL; IMAGE RECONSTRUCTION; IN VIVO STUDY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION MEASUREMENT; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; DISEASE MODEL; DRUG SCREENING; METABOLISM; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; THREE DIMENSIONAL IMAGING;

ANIMALIA; MURINAE;

3-IODOBENZYLGUANIDINE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMAGING, THREE-DIMENSIONAL; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NEUROBLASTOMA; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870403525     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0552-4     Document Type: Article

References (32)

1. DuBois SG, Matthay KK (2008) Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 35(Suppl 1): S35-S48
2. Mueller S, Matthay KK (2009) Neuroblastoma: biology and staging. Curr Oncol Rep 11:431-438
3. Matthay KK, Villablanca JG, Seeger RC et al (1999) Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173
4. Short JH, Darby TD (1967) Sympathetic nervous system blocking agents. 3. Derivatives of benzylguanidine. J Med Chem 10:833-840
5. Wieland DM, Brown LE, Tobes MC, Rogers WL, Marsh DD, Mangner TJ, Swanson DP, Beierwaltes WH (1981) Imaging the primate adrenal medulla with [123I] and [131I] meta-iodobenzylguanidine: concise communication. J Nucl Med 22:358-364
6. Taggart D, Dubois S, Matthay KK (2008) Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 52:403-418
7. Taggart DR, Han MM, Quach A et al (2009) Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 27:5343-5349
8. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL (2009) 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 50:1237-1243
9. Treuner J, Feine U, Niethammer D et al (1984) Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1:333-334
10. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, Pearson AD, Cohn SL (2010) Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 102:1319-1326
11. Matthay KK, Yanik G, Messina J et al (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25:1054-1060
12. Matthay KK, Quach A, Huberty J et al (2009) Iodine-131- metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol 27:1020-1025
13. Matthay KK, Tan JC, Villablanca JG et al (2006) Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500-506
14. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST (2005) Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20:195-199
15. Carlin S, Mairs RJ, McCluskey AG et al (2003) Development of a realtime polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 9:3338-3344
16. More SS, Itsara M, Yang X et al (2011) Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res 17:2339-2349
17. McCluskey AG, Boyd M, Ross SC, Cosimo E, Clark AM, Angerson WJ, Gaze MN, Mairs RJ (2005) [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 11:7929-7937
18. Moroz MA, Serganova I, Zanzonico P et al (2007) Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med 48:827-836
19. Autret D, Bitar A, Ferrer L, Lisbona A, Bardies M (2005) Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy. Cancer Biother Radiopharm 20:77-84
20. Matthay KK, Panina C, Huberty J et al (2001) Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 42:1713-1721
21. Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, Pearson A, Flux GD (2007) Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm 22:105-112
22. Lee CL, Wahnishe H, Sayre GA et al (2010) Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys 37:4861-4867
23. Gregory RA, Hooker CA, Partridge M, Flux GD (2009) Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system. Eur J Nucl Med Mol Imaging 36:1037-1048
24. HunterDH, Zhu X(1999) Polymer-supported radiopharmaceuticals: [131I] MIBG and [123I]MIBG. J Label Compd Radiopharm 42:653-661
25. Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houghton PJ (1997) Efficacy of oral irinotecan against neuroblastoma xenografts. Anti Cancer Drugs 8:313-322
26. Dickson PV, Hamner B, Ng CY, Hall MM, Zhou J, Hargrove PW, McCarville MB, Davidoff AM (2007) In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg 42:1172-1179
27. Iavarone A, Lasorella A, Servidei T, Riccardi R, Troncone L, Mastrangelo R (1991) Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells. J Nucl Biol Med 35:186-190
28. Yu AR, Kim JS, Kim KM et al. (2009) Optimal PET acquisition setting of 1-124 with Siemens Inveon PET: comparative simulation study with F-l 8 and microPET R4. 2009 IEEE Nuclear Science Symposium Conference Record (NSS/MIC) 2666-2668
29. Loening AM, Gambhir SS (2003) AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2:131-137
30. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023-1027
31. Waxler SH, Enger M (1954) Organ weights and obesity in mice. J Nutr 54:209-214
32. Barrett JA, Joyal JL, Hillier SM et al (2010) Comparison of highspecific-activity ultratrace 123/131I-MIBG and carrier-added 123/131IMIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm 25:299-308